Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts: 

• POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
• ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
• CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
• InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
• SHR2554: Oral EZH2 Inhibitor in R/R PTCL
• SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters:

Max S. Topp, MD
Head of Hematology and Clinical CAR-T Program Lead
Associated Professor
Medinische Klinik und Poliklinkik II
University of Wurzburg
Wurzburg, Germany

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum- University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4obcJPI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.